Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

immunity in patients affected by recurrent
disease after allogeneic bone marrow
transplantation. Hum Gen Ther
1995; 2: 813±819.
25 Bonini C, Ferrari G,Verzeletti S,
et al. HSV-TK gene transfer into donor
lymphocytes for control of allogeneic
graft-versus-leukemia. Science 1997;
276: 1719±1724.
26 Bordignon C, Notarangelo LD, Nobili
N, et al. Gene therapy in peripheral
blood lymphocytes and bone marrow
for ADA-immunodeficient patients.
Science 1995; 270: 470±475.
27 Bonini C, Ciceri F, Marktel S, Bordignon
C. Suicide-gene-transduced Tcells
for the regulation of the graft-versus-leukemia
effect [Review]. Vox Sang
1998; 74 (suppl 2): 341±343.
28 Tiberghien P. Use of donor T-lymphocytes
expressing herpes-simplex thymidine
kinase in allogeneic bone marrow
transplantation: a phase I±II study.
Hum Gene Ther 1997; 8: 615±624.
29 Tiberghien P, Ferrand C, Lioure B,
et al. Administration of herpes simplexthymidine
kinase-expressing donor T
cells with a T-cell depleted allogeneic
marrow graft. Blood 2001; 97: 63±72.
30 Champlin R, Besinger W, Henslee-
Downey J, et al. Phase I/II study of thymidine
kinase (TK)-transduced donor
lymphocyte infusions (DLI) in patients
with hematologic malignancies. Blood
1999; 94: 1448a.
31 Verzelletti S, Bonini C, Marktel S,
et al. Herpes simplex virus thymidine
kinase gene transfer for controlled
graft-versus-host disease and graft-versus-leukemia:
clinical follow-up and
improved new vectors. Hum Gene Ther
1998; 9: 2243±2251.
32 Aversa F, Tabilio A,Velardi A, et al.
Treatment of high risk acute leukemia
with T-cell-depleted stem cells from related
donors with one fully mismatched
HLA haplotype. N Engl J Med 1998;
339: 1186±1193.
33 Klingemann HG, Storb R, Fefer A,
et al. Bone marrow transplantation in
patients aged 45 years and older. Blood
1986; 67: 770.
34 Tsai T, Goodman S, Saez R, et al. Allogeneic
bone marrow transplantation in
References
patients who relapse after autologous
transplantation. Bone Marrow Transplant
1997; 20: 859.
35 Giralt S, Thall PF, Khouri I, et al.
Engraftment of allogeneic hematopoietic
progenitor cells with purine analogcontaining
chemotherapy: harnessing
graft-versus-leukemia without myeloablative
therapy. Blood 1997; 89: 4531±
4536.
36 Slavin S, Nagler A, Naparstek E, et al.
Nonmyeloablative stem cell transplantation
and cell therapy as an alternative
to conventional bone marrow transplantation
with lethal cytoreduction for
the treatment of malignant and nonmalignant
hematologic diseases. Blood
1998; 91: 756±763.
37 Khouri IF, Keating M, Korbling M,
et al. Transplant-lite: induction of graftversus-malignancy
using fludarabinebased
nonablative chemotherapy and
allogeneic blood progenitor-cell transplantation
as treatment for lymphoid
malignancies. J Clin Oncol 1998; 16:
2817±2824.
38 McSweeney PA, Niederwieser D, Shizuru
JA, et al. Hematopoietic cell transplantation
in older patients with hematologic
malignancies: replacing highdose
cytotoxic therapy with graft-versustumor
effect. Blood 2001; 97: 3390±
3400.
39 Carella AM, Cavaliere M, Lerma E, et
al. Autografting followed by nonmyeloablative
immunosuppressive chemotherapy
and allogeneic peripheralblood
hematopoietic stem-cell transplantation
as treatment of resistant
Hodgkin's disease and non-Hodgkin's
lymphoma. J Clin Oncol 1000; 18: 3918.
40 Nagler A, Slavin S,Varadi G, et al.
Allogeneic peripheral blood stem cell
transplantation using fludarabine-based
low intensity conditioning regimen for
malignant lymphoma. Bone Marrow
Transplant 2000; 25: 1021.
41 Raiola AM,Van Lint MT, Lamparelli
T, et al. Reduced intensity thiotepa-cyclophosphamide
conditioning
for allogeneic haemopoietic stem cell
transplants (HSCT) in patients up to
60 years of age. Br J Haematol 109: 716,
2000.
309